Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

BACKGROUND: Posaconazole is effective prophylaxis for invasive fungal infections (IFIs). We compared incidence of breakthrough IFI (bIFI) and early posaconazole discontinuation between patients receiving delayed-release tablet and oral suspension formulations. METHODS: This was a retrospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tallman, Gregory B, Furuno, Jon P, Noble, Brie N, Bubalo, Joseph S, Forrest, Graeme N, Lewis, James S, Bienvenida, Ana F, Holmes, Courtney A, Weber, Bo R, McGregor, Jessina C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631689/
http://dx.doi.org/10.1093/ofid/ofx163.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631689/
http://dx.doi.org/10.1093/ofid/ofx163.039

Ejemplares similares